Background
==========

Diabetes mellitus (DM) is one of the chronic illnesses with multi-system complications; the prevalence of which is alarmingly increasing \[[@B1],[@B2]\]. It is often accompanied by various chronic complications that may affect the productivity and quality of life inevitably \[[@B3]\]. Today, at least in the western world, DM is the leading cause of blindness; non-traumatic amputation; and chronic renal failure \[[@B4]\]. Diabetes reduces life expectancy by 5 to 10 years. Premature cardiovascular disease is the most common cause of mortality \[[@B5]\].

The duration of diabetes, degree of hyperglycaemia, hypertension, dyslipidaemia, and smoking are the strongest risk factors for chronic complications of diabetes \[[@B5]\]. The risk of vascular complications can thus be greatly reduced by tight management of these risk factors \[[@B5]-[@B8]\]. In fact, diabetes care is complex and requires continuing medical care and patient self-management education \[[@B6]\].

The situation is far worse in the developing world \[[@B9]\]. Indeed, coronary heart disease is already the leading cause of mortality in some developing countries \[[@B10]\]. In sub-Saharan Africa in particular, the condition is even worse due to late diagnosis and poor access to diabetes care \[[@B9]-[@B12]\].

Diabetes is not uncommon in Ethiopia but the incidence and prevalence of the disease is not well known in the community. Limited studies have shown a significant increase in its prevalence over the last four decades \[[@B13]-[@B17]\], poor access to diabetes care \[[@B18]\], and high rates of chronic complications \[[@B19]-[@B26]\]. In one of the recent studies, accesses for blood glucose monitoring and diabetes health education were found to be very low. About half of the patients didn\'t have urine analysis, renal function and lipid test done in the previous 1-2 years and none ever had glycosylated haemoglobin (HbA1c) determination. About 75% of the patients required admissions directly or indirectly due to uncontrolled diabetes \[[@B18]\]. The cost of inpatient diabetes management in the country is enormous being significantly higher than the cost of other inpatient managements \[[@B27]\].

However, diabetes in Ethiopia has never been given the attention it deserves. Glycaemic control and management of co-morbid conditions and diabetes complications are alarmingly sub-optimal and perhaps one of the worst in the world \[[@B18]\]. Furthermore, the overall disease burden in the country is unknown due to very limited studies in the country. The available studies lack generalizability due to small sample sizes most of which were limited to the capital, Addis Ababa. Besides, there is no national strategy for the prevention and control of diabetes.

The aim of this study was to describe the current situation for a group of Ethiopian diabetic patients regarding diabetes specific characteristics, assessment of hypertension management and the occurrence of diabetes related morbidities.

Methods
=======

Study design
------------

a cross-sectional study design was used.

Settings
--------

This study was conducted from August 29 to November 2, 2009 at Jimma University Specialized Hospital (JUSH). JUSH is a teaching and referral hospital located in Jimma town, Southwest Ethiopia. Diabetes clinic is one of the many chronic follow-up clinics of the hospital occurring twice weekly on Mondays and Tuesdays. The service is rendered by internists, medical residents, medical interns, and general nurses (with no special training).

Frequency of follow-up visits is at least 3 times a year and depends on proximity to hospital and need for close follow-up. Patients with evidence of complications get more frequent check-ups. On each visits, patients are usually given diabetes health education by members of Ethiopian Diabetes Society, who are non-professionals and have diabetes themselves. On the follow-up day, all patients are expected to come with results of FBS done within 48 hours. Their charts are kept at diabetes follow-up clinic.

Participants of this study were diabetic patients who have been active in follow-up for their diabetes for more than 1 year at JUSH. At the time of the study there were a total of 1716 diabetic patients (both adult and paediatric patients) on follow-up care at the hospital. Of these, 1353 were older than 15 years and were taken as a target population from which study participants were selected.

Selection of study participants
-------------------------------

a sample size of 329 patients was obtained using a minimum sample size calculation. All eligible patients who were willing to participate in the study were scrutinized until the planned sample size was obtained. They were invited to participate in the study in consecutive order and their records were reviewed after their consents were obtained. For those who had repeated clinic visits during the study period, data were collected during their first visits. For the 19 patients who declined to participate in the study, no further information was obtained from them or their records.

Data collection
---------------

The data were collected by using a structured questionnaire which was specifically prepared for this study and was compared with those used in previous studies done in the country. Patients were interviewed for their demographic features, characters related to diabetes and hypertension management where applicable, hospital admission, current symptoms, and their attitude towards care given to them. Their charts were reviewed for types of diabetes; types of treatments for diabetes and hypertension; last three records of blood glucose, BP, and weight; and causes of admission. Documented findings of laboratory data, ECG, imaging studies, eye evaluations, neurologic examinations, and diabetes complications were also sought from their medical records. Patients were interviewed in a separate room with complete privacy. Both the interviews and record reviews were done by medical interns and residents.

Data quality control
--------------------

to ensure the quality of data, data collectors were selected based on their interests and were adequately oriented and data collection was supervised by principal investigators. Information provided by patients for doses of drugs, treatment modifications, and clinical evaluations were cross checked from their records for consistency. The collected data were also checked for completeness and internal consistency.

Data processing, analysis and interpretation
--------------------------------------------

the data were coded, cleaned, entered and analysed with the help of SPSS window program version 16. Descriptive statistics was used for most variables and Chi-square test, where necessary, was used to test the association among various variables. P-value of \< 0.05 was used as statistical significance. Average blood sugar, blood pressure and weight refer to the average of the last three measures.

Ethical considerations
----------------------

Ethical approval was obtained from Jimma University Ethical review board. Informed and written consent was obtained from each study participant. People with life threatening illnesses were referred for emergency management.

Results
=======

Background Characteristics
--------------------------

The male to female ratio was 1.46:1. The mean age of patients at the time of the study was 48.4 ± 15.1 years with range of 15 to 82. The duration since DM diagnosis ranged between 1 and 41 years with a mean of 7.4 ± 5.2 years. Family history of DM was reported by a fifth of patients, with the proportion being higher among type 2 patients (Table [1](#T1){ref-type="table"}).

###### 

Background characteristic of diabetic patients on follow-up at JUSH, November 2009

  Characteristics                    Frequency   \%
  ---------------------------------- ----------- ------
  Age (years)                                    
   15 - 34                           62          18.8
   35 - 64                           212         64.4
   ≥ 65                              55          16.7
  Gender                                         
   Male                              195         59.3
   Female                            134         40.7
  Occupation                                     
   Unemployed                        115         35.0
   Farmer                            93          28.3
   Employed (paid work)              106         32.2
   Student                           15          4.6
  Literacy status                                
   Illiterate                        112         34.0
   Non-formal education              14          4.3
   Elementary                        105         31.9
   High school                       57          17.3
   Above high school                 41          12.5
  Type of diabetes                               
   Type 1                            117         35.6
   Type 2                            212         64.4
  Family history of diabetes                     
   Yes                               67          20.4
   No                                262         79.6
  Duration since diagnosis (years)               
   1-5                               157         47.7
   6-10                              106         32.2
   ≥ 11                              66          20.1
  Blood glucose on each visits                   
   Not done                          5           1.5
   FBS                               312         94.8
   RBS                               12          3.6
  Access for SMBG                                
   Yes                               18          5.5
   No                                311         94.5
  Access for drugs**\***                         
   Free                              321         97.9
   Paid                              7           2.1

RBS - random blood sugar, SMBG - self monitoring of blood glucose, FBS - fasting blood sugar

\*One patient was not taking any glucose lowering agent and was not included.

Adequacy of glycaemic control
-----------------------------

Blood glucose was measured for 98.5% of the patients during all of their last 3 visits. None of the patients ever had glycosylated haemoglobin test (Table [1](#T1){ref-type="table"}). The average FBS was comparable among both types of diabetes with mean of 171.7 ± 63.6 mg/dl. Over 2/3^rd^of both groups had a mean FBS above the target level of 130 mg/dl (Table [2](#T2){ref-type="table"}).

###### 

Patterns of glycaemic management among diabetic patients at JUSH, November 2009

  Glycemic managements                    Type 1 DM       Type 2 DM       Total                        
  --------------------------------------- --------------- --------------- --------------- ------ ----- ------
  Initial management                                                                                   
   MNT                                    4               3.4             14              6.6    18    5.5
   OGLA                                   15              12.8            188             88.7   203   61.7
   Insulin                                98              83.8            9               4.2    107   32.5
   Herbal treatment                       0               0.0             1               0.5    1     0.3
  Current management                                                                                   
   MNT alone                              0               0               1               0.5    1     0.3
   Insulin alone                          109             93.2            61              28.8   170   51.7
   Insulin and OGLA                       7               6.0             6               2.8    13    4.0
   Single OGLA                            0               0.0             69              32.5   69    21.0
   Combination OGLA                       1               0.8             75              35.4   76    23.1
  Initiation of pharmacologic treatment                                                                
   At the time of diagnosis               112             95.7            184             86.8   296   90.0
   Later on                               5               4.3             28              13.2   33    10.0
  FBS (mg/dl)                                                                                          
   \< 70                                  0               0.0             2               1.0    2     0.6
   70-130                                 24              22.4            58              28.3   82    26.3
   \> 130                                 83              77.6            145             70.7   228   73.1
  Doses of drugs (*mean****±****SD*)                                                                   
   Insuline - IU                          52.4 ± 20.1     45.0 ± 15.8     49.7 ± 19.0                  
   Glibenclamide - mg/dl                  20.0 ± 0        15.2 ± 6.5      15.3 ± 6.5                   
   Metformine- mg/dl                      625.0 ± 231.5   882.0 ± 406.1   860.8 ± 400.1                

MNT - medical nutritional therapy, OGLA -oral glucose lowering agent, FBS - fasting blood sugar

Except for 1 patient, all were on pharmacologic therapy for their diabetes at the time of study. The delay in pharmacologic treatment after diagnosis was about 3 months and was longer in type 2 patients, 1 and 4 months for type 1 and 2 respectively(p \< 0.01). At the time of the study, more than half of the patients were taking insulin alone or in combination with OGLA. The mean daily dose of glibenclamide was high with 54.0% of the patients taking at least 20 mg daily (Table [2](#T2){ref-type="table"}).

Patients taking a single OGLA alone had a better glucose levels than those taking insulin alone or combination of OGLAs or insulin and OGLA (p = 0.0006). Patients taking lower doses of oral agents also had better blood sugar control than those taking higher doses. However, a similar trend did not occur for insulin. Among patients taking combination OGLA, 56.6% were taking glibenclamide ≥20 mg/d and metformin ≥1000 mg/d and over 90% of them had sub-optimal glycaemic control. Despite having FBS well above target level over the last three visits, no modification was done for glycaemic management for 69.3% of these patients (Table [3](#T3){ref-type="table"}).

###### 

Adequacy of glycaemic management in diabetic patients on follow-up at JUSH, November 2009

                                                                 FBS                                      
  -------------------------------------------------------------- ------------ ------ ------ ------ ------ --------
  Pharmacotherapeutic options                                                                             
   Insulin alone                                                 170.8        37     23.6   120    76.4   
   Insulin and OGLA                                              190.3        3      23.1   10     76.9   0.0006
   One OGLA                                                      152.7        28     41.8   39     58.2   
   Both OGLA                                                     188.7        15     22.4   59     77.6   
  Doses of drugs                                                                                          
   Insulin                                                                                                
   \< 1IU/Kg/d                                                   167.7        36     25.5   105    74.5   0.175
   **≥**1IU/kg/d                                                 194.5        4      13.8   25     86.2   
  Glibenclamide (G)                                                                                       
   \< 20 mg/d                                                    149.4        30     50.0   30     50.0   0.0001
   **≥**20 mg/d                                                  190.0        11     15.1   62     84.9   
  Metformin(M)                                                                                            
   \< 1000 mg/d                                                  163.1        15     38.5   24     61.5   0.001
   **≥**1000 mg/d                                                204.3        5      8.9    52     91.1   
  Glibenclamide + metformin                                                                               
   G \< 20 mg/d or M \< 1000 mg/d                                168.1        12     36.4   21     63.6   0.005
   G **≥**20 mg/d & M **≥**1000 mg/d                             203.3        4      9.5    38     90.5   
  Modification of glycaemic treatment during the last 3 visits                                            
   Yes                                                           16^**\***^   19.0   70     30.7          
   No                                                            68           81.0   158    69.3          

^**\***^*In 13 of these patients treatment modification was for low FBS or symptoms of hypoglycemia.*

Level of glycaemic control was not significantly affected by sociodemographic characteristics of the patient, duration of diabetes, health education, and frequency of visits.

Assessment of Adequacy of Hypertension management
-------------------------------------------------

The mean BP over the last three visits was 124.1 ± 17.2 and 80.7 ± 9.4 mmHg for SBP and DBP respectively. At the time of the study, 44.4% of patients had already been diagnosed to have hypertension. The majority (89.0%) of them were on pharmacologic treatments. The commonly used antihypertensive drugs were ACE inhibitors. About 75% of them were taking a single antihypertensive agent (Table [4](#T4){ref-type="table"}).

###### 

Patterns of Hypertension management in diabetic patients on follow-up at JUSH, November 2009

  Characteristics                                 Frequency   (%)
  ----------------------------------------------- ----------- ------
  History of hypertension                                     
   Yes                                            146         44.4
   No                                             183         55.6
  Pharmacologic treatment for hypertension                    
   Yes                                            130         89.0
   No                                             16          11.0
  Proportion with hypertension by diabetes type               
   Type 1 (*N = 117*)                             30          20.5
   Type 2 (*N = 212*)                             116         79.5
  BP in mmHg                                                  
   \< 130/80                                      118         35.9
   130/80 to \< 140/90                            110         33.4
   140/90 to \< 160/100                           81          24.6
   ≥ 160/100                                      20          6.1
  Antihypertensive agents                                     
   HCT                                            16          12.3
   ACE inhibitor                                  110         84.6
   Beta blocker                                   10          7.7
   Calcium channel blocker                        21          16.2
   Others                                         11          8.4
  Option of drugs                                             
   Single agent                                   95          73.1
   Two drugs                                      32          24.6
   Three drugs                                    3           2.3

BP - blood pressure, HCT - hydrochlorothiazide, ACE - angiotensin converting enzyme

Only 6.8% of patients already diagnosed to have hypertension had target BP level of \<130/80 mmHg. Among patients who have never been diagnosed to have hypertension, 41.0% (75/183) had measurements higher than the target. Overall, 64.1% of the patients had BP higher than the target level at least over the last three visits. Despite having higher BP over the last three visits, only 21.8% of these patients had modification of their antihypertensive treatment (Table [5](#T5){ref-type="table"}).

###### 

Adequacy of Hypertension management in diabetic patients on follow-up at JUSH, November 2009

                                                BP (in mmHg)                       
  --------------------------------------------- -------------- ------ ----- ------ --------
  History of hypertension                                                          
   Yes                                          10             6.8    136   93.2   0.0001
   No                                           108            59.0   75    41.0   
  Pharmacologic treatment of hypertension                                          
   Yes                                          9              6.9    121   93.1   0.92
   No                                           109            54.8   90    45.2   
  Treatment modification of the last 3 visits                                      
   Yes                                          3              2.5    46    21.8   0.599
   No                                           115            97.5   165   78.2   

Assessment of efforts done to watch for and prevent diabetes related morbidities
--------------------------------------------------------------------------------

Only 68.1% of the patients had their weight measured on each visits of the last 3 with mean of 64.4 ± 12.1 Kg (59.3 ± 10.8 kg in type 1 and 67.1 ± 11.9 kg in type 2). No patient had his BMI ever done as there is no routine height measurement at the clinic (Table [6](#T6){ref-type="table"}).

###### 

Clinical follow-up patterns of diabetic patients at JUSH, November 2009

  Characteristics                                  Frequency   (%)
  ------------------------------------------------ ----------- ------------
  **Physical examination**                                     
   Weight measurements during the last 3 visits    224         68.1
   Evaluation for DM neuropathy                    31          9.4
   Diabetic eye evaluation ever                    141         42.9
  Recent finding of eye evaluation                             
    Normal                                         36          25.5
    Cataract/glaucoma                              14          9.9
    Diabetic retinopathy                           26          18.4
    No documentation                               65          46.1
  **Investigation over the last 5 years**                      
   RFT                                             97          29.5
   Urinalysis                                      216         65.6
   Lipid profile                                   16          4.9
   ECG                                             13          4.0
   Echocardiography                                9           2.7
   Ultrasound of the kidneys                       13          4.0
  **Treatments to prevent complications**                      
   Aspirin                                         46          14.0
   Lipid lowering drugs                            9           2.7
  **DM related admissions during the last year**   **39**      **10.9**
   DKA                                             28          71.8
   Hypoglycemia                                    2           5.1
   Ulcer or gangrene of extremities                5           12.8
   Stroke                                          2           5.1
   Other                                           2           5.1
  **Documented complications**                     **108**     **32.8**
   DKA                                             44          40.7
   Peripheral neuropathy                           27          25.0
   Diabetic retinopathy                            25          23.1
   Diabetic foot ulcer                             11          10.2
   Stroke/IHD                                      12          11.1
   Others                                          7           6.5
  **Current symptoms**                             ***247***   ***75.1***
   Blurring of vision                              106         32.2
   Numbness                                        100         30.4
   Polysymptoms                                    74          22.5
   Easy fatigability                               71          21.6
   Breathlessness/Chest pain/Body swelling         51          15.5
   Foot ulcer/delayed wound healing                22          6.7
   Impotence                                       15          4.6
   Others                                          21          6.4

RFT - renal function test, ECG - electrocardiography, DKA - diabetic ketoacidosis, IHD - ischemic heart disease

Diabetes eye evaluations (visual acuity and ophthalmoscopic examination) were done for only 42.9%. Of them only 35.5% were sent as part of routine evaluation. Diabetic retinopathy was documented in 18.4% of them. Among 31 for whom neurologic examination was done, 28 (90.3%) had evidence of sensory polyneuropathy (Tables [6](#T6){ref-type="table"}).

Only 29.5% (97) of the patients had renal function test (RFT) done over the last 5 years, 19.8% (19) of them had impaired renal function. Urinalysis was done for 65.7% of patients. The rates of proteinuria, glycosuria, and ketonuria were 28.7, 63.4, and 9.3% respectively (Table [6](#T6){ref-type="table"}).

Over 10% of patients reported hospital admission over the past year due to diabetes related conditions. Diabetes related complications were documented in 32.8% of the patients. About 75% of them were complaining of DM related symptoms at the time of study (Table [6](#T6){ref-type="table"}).

Patients\' satisfaction with diabetes care
------------------------------------------

Despite all the above findings, 95.3% (313) of the patients reported that they are satisfied with the care they are given at diabetic clinic of JUSH.

Discussions
===========

This study assessed a wide scope of diabetes care at Jimma University Specialized Hospital in Ethiopia using information from chart reviews and patients. Glycaemic control and blood pressure control were far below any recommended standards and attempts to prevent, detect early and manage chronic complications of diabetes were alarmingly poor. The mean FBS of 171.1 ± 63.6 mg/dl is better than the 190 ± 89.6 mg/dl in Addis Ababa \[[@B18]\] however; it is far higher than the recommendations in the developed world \[[@B6],[@B28]\]. The majority of patients (73.1%) had FBS above the target level of 130 mg/dl as compared with 79% having \>120 mg/dl in previous study \[[@B18]\] indicating that glycaemic control in Ethiopia is in dire need of being addressed. Similar to most studies in the country \[[@B18]\], no patient had HbA1c determination in this study because it is not available in public health sector in the country.

Over 99% of the patients were on pharmacologic treatment for their diabetes at the time of study with the delay after diagnosis for drug treatment being 3 months. Reasons may be lack of routine medical check-up and lack of knowledge of diabetic symptoms which resulted in patients presenting only when they were overtly sick.

Over 55% of the patients needed insulin and about 33% of type 2 patients have become insulin requiring during the course of their diabetes. This can be explained by the secondary insulin failure as the disease progresses since most patients were over 5 years post diagnosis. A similar trend has been documented in UK Prospective Diabetes Study (UKPDS) 33 in which case a significant proportion of patients on sulfonylurea subsequently required insulin due to severe hyperglycemia \[[@B7]\]. The daily insulin requirement was significantly higher in type 1 patients (52.4 Vs 45.0IU/Kg/d, p = 0.0001) which can be explained by the pathophysiology of the disease.

Patients taking a single oral agent were found to have a better glycaemic control than those taking insulin or combination OGLAs (p = 0.002). Possible explanation for this is the duration since diagnosis of diabetes as 72.5% patients taking single OGLA had diabetes for less than 5 years. In contrast, over 60% of patients requiring insulin and 56.6% of patients taking combination OGLAs had DM for over 5 years. This implies that good control in the single OGLA was due to the early disease course than the effect of the treatment given. A good illustration for this hypothesis is UKPDS 33 finding which showed progressive increments in fasting plasma glucose levels and doses of insulin and OGLA. During the follow-up period in that study, the median insulin dose increased by about 64% from 22IU at 3 years to 36IU at 12 years \[[@B7]\].

Similarly, patients taking lower doses of oral agents had a far better FBS level than those taking higher doses. More than 90% of patients taking glibenclamide \> 20 mg/d and metformin \> 1000 mg/d had persistently high FBS over the last 3+ visits. The mean FBS for them was 203.3 mg/dl and 65% of them had diabetes diagnosis for over 5 years. Surprisingly, over 80% of them did not have any modification in their glycaemic management over the last three visits. It is probably important here that patients taking such a high dose of oral agents are no more responsive to them and may sooner need insulin therapy \[**7**\]. Overall, a high FBS over the last 3 visits did not attract attention of treating physicians. In about 70% of the patients with high blood sugar, no modification in treatment regimen was done. Possible reasons are lack of awareness, time constraint, lack of adequate human power, and most importantly lack of appropriate guidelines and diabetes education for both care givers and patients.

Access for SMBG remains to be very low as it has been in previous study \[[@B18]\] (5.5 vs. 5.0%). However, access for blood glucose determination at the hospital was not found as a constraint as 98.5% of the patients had it done during each of the last three visits. Blood glucose determination is free at the hospital, but patients need to buy the glucometer and the strips for SMBG.

Morbidities and mortalities in patients having coexistence of hypertension and DM are immense \[[@B29],[@B30]\]. Due to this fact, the target BP level for diabetes is consistently dropping and has become lower than the target level of the general population \[[@B6]\]. In previous studies in Ethiopia, hypertension was found to be an associated morbidity in 19.9% of diabetic patients as in Lester FT 1988 \[[@B31]\] and 34% Feleke Y 2005 \[[@B18]\]. However, the proportion of patients with hypertension in this study is much higher than the national findings and figures in the western world \[[@B29],[@B30]\]. In this study, 44% patients have already been diagnosed with hypertension at the time of the study. Overall, 64.1% of the patients had systolic BP ≥130 mmHg and/or diastolic≥80 mmHg, and 24.6% had \>140 and/or ≥ 90 mmHg.

About 90% of patients diagnosed to have hypertension were on pharmacologic therapy, the majority of which were taking ACE inhibitors, which abides with the general recommendation \[[@B6],[@B32]\]. However, only 6.9% of patients currently taking antihypertensive medications had target BP. This figure, which does not look better than placebo effect, might have been due to under dosage, poor adherence to medications and lifestyle management, and less concern by health care providers.

The same as in the glycemic management, even though 100% of the patients had BP measurement on each visits; it was rarely used for patient management. Among patients not considered to have hypertension, 41.0% had mean BP of hypertensive ranges over the last 3 visits. Despite having BP of hypertensive range over the last three visits, 79.2% of the patients did not have modification to their hypertension regimen.

The proportion of patients who have been evaluated for diabetes related morbidities is very low. Less than 30% had RFT done and about 35% of patients did not have urinalysis within the last 5 years. Less than 5% of the patients had ECG, echocardiography, lipid test, or ultrasound of the kidneys. Alarmingly a significant proportion of tested patients had abnormal findings. Most of the imaging studies would have been expensive and inaccessible in the hospital setting; however, urine dipstick for albumin test is cheap and readily available at the hospital.

Far from recommended practice less than 10% of patients had ever had an evaluation for diabetic neuropathy. Those who had been examined were those with disabling symptoms as 90.3% of those evaluated had evidences for peripheral sensory polyneuropathy. Similarly, only 42.9% of patients in this study ever had a recommended yearly eye evaluation and the majority were evaluated for their symptoms rather than as a routine screening follow-up.

Diabetic ketoacidosis was found to be the commonest cause of hospital admission. Peripheral neuropathy and retinopathy were the most typical chronic complications identified. These findings are compatible with previous studies in Ethiopia \[[@B19]\] and other countries in Africa \[[@B22]-[@B26]\]. Similarly, the chief complaints for most patients were eye and sensory related. A significant proportion of them also had polysymptoms of diabetes that indicates poor sugar control.

Lifestyle management is an important component of diabetic care \[[@B6]\] and intensive nutrition treatment besides the conventional pharmacotherapy has been shown to improve both glycaemic control and anthropometric measures \[[@B33]\]. In this regard, diabetes nurse educators and diabetes dietitian play an important role in diabetic care. However, no emphasis has been given to diabetes health education at the clinic and in Ethiopia in general. To date there are no diabetes nurse educators and diabetes dietitian in the country. Those rendering health service for diabetes patients at the hospital had no special training for diabetes care and most of them were medical interns who were naïve not only to diabetes care but also to the general medical practice.

Demographic backgrounds, type and duration of DM since diagnosis, and duration of pharmacologic treatment of hyperglycemia were not found to affect level of glycaemic control. Similarly, the influences of good glycemic and hypertension control on morbidity were not observed in this study probably due to two major reasons. Firstly, most of the patients did not have adequate glycaemic and BP control. Secondly, documentation for diabetes related morbidities was found for only 1/3^rd^of patients.

Most alarming is that there is very poor record keeping system and widespread trend of not documenting physical findings, laboratory results, and reason for changing managements. Despite this, the majority of the patients reported that they were satisfied with the care they were given at the clinic indicating that patients have inappropriate expectation about diabetes care. Poor awareness among patients about the extent and components of diabetes care affects not only their expectations but importantly the quality of services they obtain and the outcome of diabetes. In this study it may be mentioned here that patients might have been satisfied with the free laboratory services (for blood glucose) and medications, which were probably their main expectations of the care.

The strengths of our study was the high patient response rate, good cooperation from hospital staff, and the fact that it was one of the few studies on diabetes care in Ethiopia.

There are potential shortcomings in our study that require comment. The major limitation was poor chart keeping that might have limited us from getting full information about chronic complications of diabetes. Another limitation was the cross-sectional study design that is not adequate to assess most of the chronic complications of diabetes. The classification of diabetes to type 1 and type 2 was based solely on history and age of the patient. In this study, the proportion of type1 was 35.6% which is much higher than findings in the western world of 5 -10% \[[@B6]\]. We thus think that the proportion of type 1 diabetes may be lower than our finding with appropriate antibody study.

Conclusions
===========

Glycaemic and hypertension controls in diabetic patients at JUSH were far below any recommended standards and attempts to prevent, detect early, and manage chronic complications of diabetes were alarmingly poor. Besides these, inadequate knowledge and perception of patients about the scope of diabetic management and trends of poor documentation at the clinic were major constraints identified affecting over all care of diabetes patients.

Thus, we strongly recommend that urgent action should be taken to improve the management of such an alarmingly increasing morbidity that, if not acted upon, is debilitating to the patient and heavy burden to the economy of the country in particular. Due emphasis should be given to clinical examination and urine albumin test to screen for chronic complications of diabetes which are highly cost effective in such resource constraint settings. Available information should also be carefully interpreted and the findings be acted upon timely and appropriately. The documentation systems not only for diabetic patients but also for the general medical practice should improve so that patients will obtain an optimum and timely care. Further clinical investigations for adequacy of diabetes care and diabetes complications with appropriate parameters are also warmly recommended.
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